Results 251 to 260 of about 6,007,439 (376)

Financial Distress and Its Determinants in Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Objective To quantify the degree of financial distress and identify its determinants in adults with rheumatoid arthritis (RA) given the frequent prolonged use of expensive disease‐modifying therapies. Methods We identified adults enrolled in the FORWARD databank with either RA or noninflammatory musculoskeletal disease (NIMSKD) completing the ...
Amber Brown Keebler, Yunju Im, Sofia Pedro, Ted R. Mikuls, Edward S. Peters, Kaleb Michaud   +5 more
wiley   +1 more source

Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective

British medical journal, 2016
N. Lineberry, J. Berlin, Bernadette Mansi, Susan Glasser, M. Berkwits, Christian Klem, Ananya Bhattacharya, L. Citrome, R. Enck, J. Fletcher, Daniel G Haller, Tai-Tsang Chen, C. Laine   +12 more
semanticscholar   +1 more source

Testing A Personalized Approach to Chronic Low Back Pain: A Randomized Controlled Trial in Older Veterans

Arthritis Care &Research, Accepted Article.
Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner, Angela Gentili, Meika A. Fang, Edward Garay, Laura Lawson, Lenore Joseph, Cathy C. Lee, Michelle I. Rossi, Beverly Thorn, Subashan Perera   +9 more
wiley   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. [PDF]

PLoS One
Shi Y, Guan S, Wang S, Li M, Yu Y, Liu J, Yang W, Wang Z.   +7 more
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Methods of Adverse Event Detection in Intensive Care: A Systematic Review. [PDF]

Crit Care Explor
Gorman J, Rewa O, Kung J, Widder S, Slemko J.   +4 more
europepmc   +1 more source

Sex differences in medication discontinuation in axial spondyloarthritis.

Arthritis Care &Research, Accepted Article.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Correction: Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS). [PDF]

Front Pharmacol
Che X, Zhu Y.
europepmc   +1 more source

Adverse events following immunization with pentavalent vaccine in a tertiary care hospital

, 2017
Sharad Bansal
openalex   +2 more sources